News
-
-
-
-
REGULATED PRESS RELEASE
Novembre 2025 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Communiqué mensuel sur le nombre de droits de vote et d'actions de la société bioMérieux. Informations conformes à la réglementation financière en vigueur -
-
-
-
PRESS RELEASE
Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results, Highlighting the Therapy's Potential for Patients with Hereditary Hemorrhagic Telangiectasia
Vaderis Therapeutics announces publication of engasertib proof-of-concept study results in The New England Journal of Medicine, showing potential for Hereditary Hemorrhagic Telangiectasia patients -
-
PRESS RELEASE
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Aspire Biopharma Holdings, Inc. submits Pre-IND meeting request to FDA for fast-acting sublingual aspirin formulation to treat acute myocardial infarction, demonstrating rapid action and potential for FDA approval
